Divis Laboratories Ltd Share Price

Q: What is the share price of Divis Laboratories Ltd today?

Divis Laboratories Ltd share price as on 18 Mar 2025 is ₹5772.95

Pharmaceuticals

NSE: DIVISLAB Large Cap ISIN: INE361B01024

As on 18 March 2025 at 22:09 IST

₹5,772.95

+ 102.10

(1.80%)

Sell Buy

Q3 Results:

Divis Laboratories Ltd Q3 Results:Total income in Q3 FY25 rose 23.1% to ₹2,401 crores, from ₹1,950 crores in the same period last year. Net profit increased 64.5% to ₹589 crores on a yearly basis, compared to ₹358 crores in Q3 FY24.

About Divis Laboratories Ltd

Divis Laboratories Ltd was established in 1990. The company is a prominent player in the pharmaceuticals and drugs sector. Its headquarters is in Hyderabad, India. The company has decades of experience in manufacturing Active Pharmaceutical Ingredients (APIs). It also has expertise in Nutraceutical Ingredients. They even provide Custom Synthesis of APIs for major pharmaceutical companies. The company is renowned for its extensive range of products. This includes generic APIs such as Naproxen and Dextromethorphan. It also includes Gabapentin, Pregabalin, and Valsartan. The product list also includes Levetiracetam and Phenylephrine. +

Over 1 Month

-4.27%

Over 6 Months

4.01%

Over 1 Year

61.72%

Over 3 Years

25.90%

Divis Laboratories Ltd Summary

Close ₹5,772.95

Open ₹5,680

High ₹5,809

Low ₹5,627

Volume 3,97,067

Net Turnover (in Cr) ₹227.54

52Wk High ₹6,285.45

52Wk Low ₹3,350

52Wk High / Low

3,350

6,285.45

Divis Laboratories Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹1,53,253.68

EPS (TTM) 78.09

Book Value (BV) 513.62

Div. Yield 0.52 %

P/E (TTM) 73.99

Price/Book Value 11.25

Delivery % 42.94 %

Face Value 2

Key Ratios

PE Ratio 57.79

PB Ratio 6.75

EV to Sales 11.39

PEG Ratio -4.50

ROA 11.66

ROE 12.04

Debt-Equity -

Net Profit Margin 20.56

Operating Profit Margin 32.77

Divis Laboratories Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	8,184	8,112	9,073.70	7,031.96	5,584.05
Total Expenses	6,021	5,743	5,390.20	4,365.92	3,764.59
Profit Before Tax	2,163	2,369	3,683.50	2,666.04	1,819.46
Profit After Tax	1,600	1,824	2,960.45	1,984.29	1,376.54
Operating Profit after Depreciation	2,166	2,370	3,684.30	2,666.91	1,825.56

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	4,739	4,722	4,325.05	3,703.87	2,781.85
Total Non Current Assets	5,795	5,127	5,023.21	4,599.36	3,855.87
Total Current Assets	9,675	9,312	8,351.50	6,174.71	4,679.83
TOTAL ASSETS	15,470	14,439	13,374.71	10,774.07	8,535.70
Total Shareholder's Fund	13,571	12,767	11,728.18	9,294.61	7,309.92

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	1,261	2,459	1,911.80	1,946.93	1,215.94
Net Cash used in Investing Activities	-269	-2,707	-2,194.92	75.13	-83.47
Net Cash used in Financing Activities	-799	-797	-532.44	-34.89	-1,091.42

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	8,002	7,974	8,991.08	6,861.14	5,500.43
Total Expenses	5,870	5,620	5,314.56	4,233.27	3,687.14
Profit Before Tax	2,132	2,354	3,676.52	2,627.87	1,813.29
Profit After Tax	1,576	1,808	2,948.54	1,954.72	1,372.71
Operating Profit after Depreciation	2,135	2,355	3,677.17	2,628.56	1,819.35

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	4,737	4,719	4,320.97	3,699.01	2,776.26
Total Non Current Assets	5,790	5,116	5,011.90	4,598.46	3,852.94
Total Current Assets	9,572	9,236	8,295.96	6,125.31	4,661.17
TOTAL ASSETS	15,362	14,352	13,307.86	10,723.77	8,514.11
Total Shareholder's Fund	13,484	12,705	11,691.35	9,271.57	7,316.69

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	1,266	2,447	1,910.16	1,947.05	1,208.47
Net Cash used in Investing Activities	-268	-2,707	-2,195.40	75.34	-81.38
Net Cash used in Financing Activities	-798	-796	-531.50	-33.97	-1,091.25

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	2,319	2,338	2,118	2,303	1,855
Total Expenses	1,576	1,622	1,496	1,572	1,366
Profit Before Tax	726	722	604	713	489
Profit After Tax	589	510	430	538	358
Operating Profit after Depreciation	825	822	701	810	584

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	2,297	2,302	2,063	2,259	1,808
Total Expenses	1,550	1,573	1,442	1,542	1,317
Profit Before Tax	730	735	603	700	490
Profit After Tax	594	518	430	531	358
Operating Profit after Depreciation	829	834	700	796	585

Divis Laboratories Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 5,603.60

S2 5,536.35

S3 5,490.65

Pivot 5,649.30

R1 5,716.55

R2 5,762.25

R3 5,829.50

Moving Average

20 SMA 5,677.17

50 SMA 5,785.08

100 SMA 5,862.10

200 SMA 5,420.80

Divis Laboratories Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Divis Laboratories Ltd

₹30/Share

Announcement Date 02 Aug 2024

Record Date 02 Aug 2024

Div Yield 1500%

AGM Date: 22 Aug 2022

AGM 22/08/2022 We enclose herewith copies of notice to shareholders of the Company published in newspapers intimating that the 32nd Annual General Meeting of the Company is scheduled to be held on Monday, August 22, 2022 at 10.00 A.M. IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) including other details as mentioned therein. This notice was published on July 20, 2022 in Financial Express (English daily - All editions) and Andhra Prabha (Telugu daily - Hyderabad edition). (As Per BSE Announcement Dated on 20.07.2022) This is to inform that the 32nd Annual General Meeting (AGM) of the Company was held on August 22, 2022 at 10.00 a.m. through Video Conferencing ('VC') / Other Audio-Visual Means ('OAVM') and the business mentioned in the Notice convening the AGM dated May 23, 2022 was duly transacted. In this regard, we hereby submit the following: 1. Summary of proceedings of the 32nd Annual General Meeting along with copy of the Chairman's speech and Managing Director's speech delivered at the AGM as Annexure - I; 2. Voting Results as required under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as Annexure - II; 3. The Report of Scrutinizer on remote e-voting and voting at AGM (by electronic means) as Annexure - III. Please note that all the resolutions set out in the Notice of 32nd AGM were passed with requisite majority. This is for your information and records. (As Per BSE Announcement Dated on 22.08.2022)

AGM Date: 28 Aug 2023

The 33rd Annual General Meeting of the Company is scheduled to be held on Monday, AUgust 28, 2023 at 10.00 A.M. IST. Intimation of record date. Notice informing 33rd Annual General Meeting of the Company to be held on August 28, 2023 through Video Conferencing / Other Audio-visual Means, Record date for dividend and other information. (As Per BSE Announcement Dated on 28.07.2023) Notice of 33rd Annual General Meeting and Annual Report for the financial year 2022-23 (As Per BSE Announcement dated on 02.08.2023) Submisssion of proceedings of 33rd Annual General Meeting, Voting Results and report of Scrutinizer. Submission of Scrutinizer''s report on voting results of 33rd Annual General Meeting held on August 28, 2023. (As per BSE Announcement Dated on 28/08/2023)

AGM Date: 12 Aug 2024

The 34 th AGM of the Members of the Company will be held on Monday, August 12, 2024. The record date for the purpose of the payment of dividend is August 02, 2024 Please find the enclosed Notice of 34th Annual General Meeting of the Company. (As Per BSE Announcement dated on 15.07.2024) Please find the enclosed scrutinizers report on the AGM resolutions along with proceedings of the AGM and Voting results. (As Per BSE Announcement Dated on: 12/08/2024)

Divis Laboratories Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceuticals Industries Ltd	₹1,748.60	₹4,19,547.71
Cipla Ltd	₹1,508.70	₹1,21,844.87
Torrent Pharmaceuticals Ltd	₹3,135.60	₹1,06,118.19
Dr Reddys Laboratories Ltd	₹1,164.70	₹97,189.02
Lupin Ltd	₹2,035.30	₹92,919.78

Divis Laboratories Ltd Top Mutal Funds Invested

Fund Name	AUM
SBI Equity Hybrid Fund	3.44%
SBI Bluechip Fund	3.24%
SBI Focused Equity Fund	3.83%
AXIS ELSS Tax Saver Fund	2.51%
Nippon India Pharma Fund	9.32%

Divis Laboratories Ltd News

Volumes jump at Divis Laboratories Ltd counter

Divis Laboratories Ltd witnessed volume of 24583 shares by 10:47 IST on BSE, a 8.7 times surge over two-week average daily volume of 2824 shares

12 Mar 2025, 11:00 am

Divis Laboratories Ltd spurts 2.08%, up for third straight session

Divis Laboratories Ltd is quoting at Rs 6093.9, up 2.08% on the day as on 12:49 IST on the NSE. The stock is up 63.83% in last one year as compared to a 6.22% spurt in NIFTY and a 16.02% spurt in the Nifty Pharma index.

13 Feb 2025, 01:05 pm

Divis Laboratories Ltd spurts 0.38%, gains for fifth straight session

Divis Laboratories Ltd is quoting at Rs 6146.65, up 0.38% on the day as on 12:44 IST on the NSE. The stock is up 64.71% in last one year as compared to a 7.64% jump in NIFTY and a 18.78% jump in the Nifty Pharma.

06 Feb 2025, 01:00 pm

Divis Laboratories Ltd up for third straight session

Divis Laboratories Ltd is quoting at Rs 6074, up 3.23% on the day as on 12:49 IST on the NSE. The stock is up 64.18% in last one year as compared to a 8.43% jump in NIFTY and a 18.5% jump in the Nifty Pharma index.

04 Feb 2025, 01:05 pm

Divi's Labs spurts as PAT soars 65% YoY to Rs 589 crore in Q3

Divi's Laboratories jumped 4.31% to Rs 5,864.55 after the pharma major's consolidated net profit surged 64.53% to Rs 589 crore on 25.01% rise in revenue from operations to Rs 2,319 crore in Q3 FY25 over Q3 FY24.

03 Feb 2025, 02:14 pm

Divis Laboratories Ltd Stock Analysis

Annual revenue for Divis Laboratories Ltd increased by 0.35% to ₹8,002 crore in FY 2024 from ₹7,974 crore in FY 2023.
Annual Net Profit for Divis Laboratories Ltd decreased by 12.83% to ₹1,576 crore in FY 2024 from ₹1,808 crore in FY 2023.
Promoter Shareholding in Divis Laboratories Ltd remains unchanged by 0.00% in the most recent quarter, from 51.89% in September 2024 to 51.89% in December 2024.
Divis Laboratories Ltd delivered a 1-year return of 61.72% compared to the Nifty 50, which provided a return of 2.05% as of the last trading session.
Divis Laboratories Ltd share price moved up by 1.80% from its previous close of INR ₹5,670.85. The latest Divis Laboratories Ltd share price is INR ₹5,772.95.
Divis Laboratories Ltd share price today has been at a low of 5,627 and a high of 5,809. Over the past 52 weeks, the Divis Laboratories Ltd share price has seen a low of 3,350 and a high of 6,285.45.

About Divis Laboratories Ltd

Divis Laboratories Ltd. was established in 1990. The company is a prominent player in the pharmaceuticals and drugs sector. Its headquarters is in Hyderabad, India. The company has decades of experience in manufacturing Active Pharmaceutical Ingredients (APIs). It also has expertise in Nutraceutical Ingredients. They even provide Custom Synthesis of APIs for major pharmaceutical companies.

The company is renowned for its extensive range of products. This includes generic APIs such as Naproxen and Dextromethorphan. It also includes Gabapentin, Pregabalin, and Valsartan. The product list also includes Levetiracetam and Phenylephrine. Additionally, Divis Laboratories produces nutraceutical ingredients like beta-carotene and Lutein. It also produces Astaxanthin and Lycopene. The company also produces Vitamin D3 and Vitamin A. These products highlight the company’s duty to quality and innovation.

Divis Laboratories Ltd. is led by its founder and Managing Director, Dr Murali K. Divi, and the Whole-time Director, Mr Kiran S. Divi. The promoters hold a significant shareholding of approximately 51.90%. This reflects their strong commitment to the company’s growth and success.
Here are the top managing promoters of the company:

Ramesh B V Nimmagadda
Murali K Divi
Kiran S Divi
Nilima Prasad Divi
S Devendra Rao

The registered office of Divis Laboratories Ltd. is located at 10 & 13 - A, S V Road, Mumbai, Maharashtra 400102. The company’s management team continues to drive its vision. They deliver high-quality pharmaceutical products to meet global healthcare needs.
The company is one of the leading manufacturers of generic APIs globally. Divis Laboratories Ltd. has established itself as a major player in the pharmaceutical industry. It has large-scale manufacturing capabilities. It also adheres to global regulatory standards, which have earned it a reputable position in the market.

History of the Company

Dr. Murali K. Divi founded Divis Laboratories Ltd. It has grown to become a significant player in the global pharmaceutical industry. It was initially established as Divis Research Central. The company focused on developing commercial processes. This was for manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates. In 1994, the company rebranded to Divis Laboratories Ltd. This signalled its intent to enter the API and intermediates manufacturing industry.

The company’s first manufacturing facility was set up in 1995 at Choutuppal, Telangana. This facility marked the beginning of Divis’ journey in large-scale manufacturing. The company received ISO-9002 certification from SGS-Yarsley of the UK in 1997. This certification highlights its commitment to quality standards. By 1999, Divis Laboratories had earned a Certificate of Suitability (CoS) from the European Directorate. This certification was for the quality of its Naproxen production.

In 2002, Divis Laboratories expanded its manufacturing capabilities. They established a second facility at Chippada near Visakhapatnam. This expansion was crucial for meeting the growing global demand for APIs and intermediates. The company went public with its initial public offering (IPO) on February 17, 2003. The IPO further solidified its financial foundation and enabled future growth.

Significant milestones marked the early 2000s for Divis Laboratories. The company received multiple certifications, including ISO-14001, from SGS International AG of Switzerland. It also received OHSAS-18001 from BVQI of London. These reflect its adherence to international standards in quality and occupational health and safety. The US FDA also inspected and approved the company’s facilities. This approval underlines its compliance with stringent regulatory requirements.

In 2010, Divis Laboratories Ltd. established a research centre in Hyderabad. It was to focus on fundamental research in niche business segments. This move aimed to enhance the company’s R&D capabilities and foster innovation. Over the years, Divis Laboratories has continued to expand its product portfolio. This includes a wide range of generic APIs such as Naproxen, Gabapentin, and Dextromethorphan. It also includes Valsartan, Levetiracetam, Phenylephrine, and Pregabalin. The company also produces nutraceutical ingredients like Lutein, beta-carotene, and Lycopene. It also produces Astaxanthin, Vitamin A1, and Vitamin D3.

Divis Laboratories Ltd. has established itself as a leading manufacturer of generic APIs globally. It has a significant market share in products like Naproxen, Dextromethorphan, and Gabapentin. The company’s API production is backward integrated. This ensures a reliable supply chain and cost efficiency. Divis Laboratories also offers custom synthesis services. They provide contract development and manufacturing (CDMO) offers. It also offers contract research manufacturing services (CRAMS) for some of the world’s largest pharmaceutical companies.

The company is committed to quality, innovation, and sustainability. This has earned it many awards and recognitions from various regulatory and statutory bodies. Divis Laboratories has been honoured for its manufacturing, environment, health, and safety excellence. Today, Divis Laboratories Ltd. continues to be led by its founder, Dr Murali K. Divi, and the full-time director, Mr Kiran S. Divi. The promoters hold a large shareholding, reflecting their strong obligation to the company’s growth and success.

With many decades of experience, Divis Laboratories Ltd. remains dedicated and continue to deliver high-quality pharmaceutical products to meet global healthcare needs. The company has large-scale manufacturing capabilities. It adheres to global regulatory standards and focuses on innovation. These features position it as a significant player in the pharmaceutical industry.